Clinical grade expansion of MSCs

Immunology Letters

Volumn 168, Issue 2, 2015, Pages 222-227

  Capelli, C ^a   Pedrini, O ^a   Valgardsdottir, R ^a   Da Roit, F ^a   Golay, J ^a   Introna, M ^a  

^a Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

Author keywords

Cell therapy; Good manufacturing practices; Mesenchymal stromal cells

Indexed keywords

REAGENT;

ARTICLE; CELL COUNT; CELL ISOLATION; CULTURE MEDIUM; GOOD MANUFACTURING PRACTICE; HUMAN; IN VITRO STUDY; MESENCHYMAL STROMA CELL; PRIORITY JOURNAL; REPRODUCIBILITY; STEM CELL CULTURE; STEM CELL EXPANSION; STEM CELL TRANSPLANTATION; ANIMAL; BONE MARROW CELL; CELL CULTURE; CELL CULTURE TECHNIQUE; CELL PROLIFERATION; CYTOLOGY; IMMUNOPHENOTYPING; KARYOTYPING; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; PROCEDURES; UMBILICAL CORD;

ANIMALS; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; IMMUNOPHENOTYPING; KARYOTYPING; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; REPRODUCIBILITY OF RESULTS; UMBILICAL CORD;

EID: 84949624496     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2015.06.006     Document Type: Article

References (75)

1. Maumus M., Guerit D., Toupet K., Jorgensen C., Noel D. Mesenchymal stem cell-based therapies in regenerative medicine: applications in rheumatology. Stem Cell Res. Ther. 2011, 2:14.
2. Williams A.R., Hare J.M. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ. Res. 2011, 109:923-940.
3. Jones E., Yang X. Mesenchymal stem cells and bone regeneration: current status. Injury 2011, 42:562-568.
4. Shi Y., Su J., Roberts A.I., Shou P., Rabson A.B., Ren G. How mesenchymal stem cells interact with tissue immune responses. Trends Immunol. 2012, 33:136-143.
5. Auletta J.J., Deans R.J., Bartholomew A.M. Emerging roles for multipotent, bone marrow-derived stromal cells in host defense. Blood 2012, 119:1801-1809.
6. Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell 2012, 10:709-716.
7. Dazzi F., Lopes L., Weng L. Mesenchymal stromal cells: a key player in 'innate tolerance. Immunology 2012, 137:206-213.
8. Le Blanc K., Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat. Rev. Immunol. 2012, 12:383-396.
9. Bernardo M.E., Fibbe W.E. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 2013, 13:392-402.
10. Ankrum J.A., Ong J.F., Karp J.M. Mesenchymal stem cells: immune evasive, not immune privileged. Nat. Biotechnol. 2014, 32:252-260.
11. von Bahr L., Batsis I., Moll G., Hagg M., Szakos A., Sundberg B., Uzunel M., Ringden O., Le Blanc K. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells 2012, 30:1575-1578.
12. Eggenhofer E., Benseler V., Kroemer A., Popp F.C., Geissler E.K., Schlitt H.J., Baan C.C., Dahlke M.H., Hoogduijn M.J. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front. Immunol. 2012, 3:297.
13. Henschler R., Deak E., Seifried E. Homing of Mesenchymal Stem Cells 2008, vol. 35:306-312. Transfusion medicine and hemotherapy: offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie.
14. Maurya D.K., Doi C., Pyle M., Rachakatla R.S., Davis D., Tamura M., Troyer D. Non-random tissue distribution of human naive umbilical cord matrix stem cells. World J. Stem Cells 2011, 3:34-42.
15. Guezguez B., Campbell C.J., Boyd A.L., Karanu F., Casado F.L., Di Cresce C., Collins T.J., Shapovalova Z., Xenocostas A., Bhatia M. Regional localization within the bone marrow influences the functional capacity of human HSCs. Cell Stem Cell 2013, 13:175-189.
16. Lee R.H., Pulin A.A., Seo M.J., Kota D.J., Ylostalo J., Larson B.L., Semprun-Prieto L., Delafontaine P., Prockop D.J. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009, 5:54-63.
17. Choi H., Lee R.H., Bazhanov N., Oh J.Y., Prockop D.J. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kappaB signaling in resident macrophages. Blood 2011, 118:330-338.
18. Roccaro A.M., Sacco A., Maiso P., Azab A.K., Tai Y.T., Reagan M., Azab F., Flores L.M., Campigotto F., Weller E., Anderson K.C., Scadden D.T., Ghobrial I.M. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J. Clin. Investig. 2013, 123:1542-1555.
19. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
20. Bacigalupo A. Management of acute graft-versus-host disease. Br. J. Haematol. 2007, 137:87-98.
21. Deeg H.J. How I treat refractory acute GVHD. Blood 2007, 109:4119-4126.
22. Perez L., Anasetti C., Pidala J. Have we improved in preventing and treating acute graft-versus-host disease. Curr. Opin. Hematol. 2011, 18:408-413.
23. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
24. Sensebe L., Gadelorge M., Fleury-Cappellesso S. Production of mesenchymal stromal/stem cells according to good manufacturing practices: a review. Stem Cell Res. Ther. 2013, 4:66.
25. Verbeek R. Generation of mesenchymal stem cells as a medicinal product in organ transplantation. Curr. Opin. Org. Transplant. 2013, 18:65-70.
26. Bieback K., Kinzebach S., Karagianni M. Translating research into clinical scale manufacturing of mesenchymal stromal cells. Stem Cells Int. 2010, 2011:193519.
27. Sensebe L., Krampera M., Schrezenmeier H., Bourin P., Giordano R. Mesenchymal stem cells for clinical application. Vox Sang. 2010, 98:93-107.
28. Grisendi G., Anneren C., Cafarelli L., Sternieri R., Veronesi E., Cervo G.L., Luminari S., Maur M., Frassoldati A., Palazzi G., Otsuru S., Bambi F., Paolucci P., Pierfranco C., Horwitz E., Dominici M. GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. Cytotherapy 2010, 12:466-477.
29. Aktas M., Radke T.F., Strauer B.E., Wernet P., Kogler G. Separation of adult bone marrow mononuclear cells using the automated closed separation system Sepax. Cytotherapy 2008, 10:203-211.
30. Hanley P.J., Mei Z., Durett A.G., Cabreira-Harrison Mda G., Klis M., Li W., Zhao Y., Yang B., Parsha K., Mir O., Vahidy F., Bloom D., Rice R.B., Hematti P., Savitz S.I., Gee A.P. Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System. Cytotherapy 2014, 16:1048-1058.
31. Lin Y., Hogan W.J. Clinical application of mesenchymal stem cells in the treatment and prevention of graft-versus-host disease. Adv. Hematol. 2011, 2011:427863.
32. Ringden O., Uzunel M., Rasmusson I., Remberger M., Sundberg B., Lonnies H., Marschall H.U., Dlugosz A., Szakos A., Hassan Z., Omazic B., Aschan J., Barkholt L., Le Blanc K. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
33. Herrmann R., Sturm M., Shaw K., Purtill D., Cooney J., Wright M., Phillips M., Cannell P. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study. Int. J. Hematol. 2012, 95:182-188.
34. Muller I., Kordowich S., Holzwarth C., Isensee G., Lang P., Neunhoeffer F., Dominici M., Greil J., Handgretinger R. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol. Dis. 2008, 40:25-32.
35. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., Lanino E., Sundberg B., Bernardo M.E., Remberger M., Dini G., Egeler R.M., Bacigalupo A., Fibbe W., Ringden O. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
36. Sundin M., Ringden O., Sundberg B., Nava S., Gotherstrom C., Le Blanc K. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 2007, 92:1208-1215.
37. Capelli C., Domenghini M., Borleri G., Bellavita P., Poma R., Carobbio A., Mico C., Rambaldi A., Golay J., Introna M. Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. Bone Marrow Transplant. 2007, 40:785-791.
38. Bieback K., Hecker A., Kocaomer A., Lannert H., Schallmoser K., Strunk D., Kluter H. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 2009, 27:2331-2341.
39. Doucet C., Ernou I., Zhang Y., Llense J.R., Begot L., Holy X., Lataillade J.J. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J. Cell. Physiol. 2005, 205:228-236.
40. Lucarelli E., Beccheroni A., Donati D., Sangiorgi L., Cenacchi A., Del Vento A.M., Meotti C., Bertoja A.Z., Giardino R., Fornasari P.M., Mercuri M., Picci P. Platelet-derived growth factors enhance proliferation of human stromal stem cells. Biomaterials 2003, 24:3095-3100.
41. Warnke P.H., Humpe A., Strunk D., Stephens S., Warnke F., Wiltfang J., Schallmoser K., Alamein M., Bourke R., Heiner P., Liu Q. A clinically-feasible protocol for using human platelet lysate and mesenchymal stem cells in regenerative therapies. J. Craniomaxillofac. Surg. 2013, 41:153-161.
42. Schallmoser K., Rohde E., Bartmann C., Obenauf A.C., Reinisch A., Strunk D. Platelet-derived growth factors for GMP-compliant propagation of mesenchymal stromal cells. Biomed. Mater. Eng. 2009, 19:271-276.
43. Schallmoser K., Rohde E., Reinisch A., Bartmann C., Thaler D., Drexler C., Obenauf A.C., Lanzer G., Linkesch W., Strunk D. Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum. Tissue Eng. C Methods 2008, 14:185-196.
44. Schallmoser K., Bartmann C., Rohde E., Reinisch A., Kashofer K., Stadelmeyer E., Drexler C., Lanzer G., Linkesch W., Strunk D. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion (Paris) 2007, 47:1436-1446.
45. Lange C., Cakiroglu F., Spiess A.N., Cappallo-Obermann H., Dierlamm J., Zander A.R. Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine. J. Cell. Physiol. 2007, 213:18-26.
46. Wuchter P., Bieback K., Schrezenmeier H., Bornhauser M., Muller L.P., Bonig H., Wagner W., Meisel R., Pavel P., Tonn T., Lang P., Muller I., Renner M., Malcherek G., Saffrich R., Buss E.C., Horn P., Rojewski M., Schmitt A., Ho A.D., Sanzenbacher R., Schmitt M. Standardization of good manufacturing practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. Cytotherapy 2015, 17:128-139.
47. Castiglia S., Mareschi K., Labanca L., Lucania G., Leone M., Sanavio F., Castello L., Rustichelli D., Signorino E., Gunetti M., Bergallo M., Bordiga A.M., Ferrero I., Fagioli F. Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions. Cytotherapy 2014, 16:750-763.
48. Martins J.P., Santos J.M., de Almeida J.M., Filipe M.A., de Almeida M.V., Almeida S.C., Agua-Doce A., Varela A., Gilljam M., Stellan B., Pohl S., Dittmar K., Lindenmaier W., Alici E., Graca L., Cruz P.E., Cruz H.J., Barcia R.N. Towards an advanced therapy medicinal product based on mesenchymal stromal cells isolated from the umbilical cord tissue: quality and safety data. Stem Cell Res. Ther. 2014, 5:9.
49. Bernardo M.E., Avanzini M.A., Perotti C., Cometa A.M., Moretta A., Lenta E., Del Fante C., Novara F., de Silvestri A., Amendola G., Zuffardi O., Maccario R., Locatelli F. Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. J. Cell. Physiol. 2007, 211:121-130.
50. Ikebe C., Suzuki K. Mesenchymal stem cells for regenerative therapy: optimization of cell preparation protocols. BioMed Res. Int. 2014, 2014:951512.
51. Capelli C., Gotti E., Morigi M., Rota C., Weng L., Dazzi F., Spinelli O., Cazzaniga G., Trezzi R., Gianatti A., Rambaldi A., Golay J., Introna M. Minimally manipulated whole human umbilical cord is a very rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate. Cytotherapy 2011, 13(7):786-801.
52. Capelli C., Salvade A., Pedrini O., Barbui V., Gotti E., Borleri G., Cabiati B., Belotti D., Perseghin P., Bellavita P., Biondi A., Biagi E., Rambaldi A., Golay J., Introna M. The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs. Cytotherapy 2009, 11:403-413.
53. Sensebe L. Clinical grade production of mesenchymal stem cells. Biomed. Mater. Eng. 2008, 18:S3-S10.
54. Robey P.G., Kuznetsov S.A., Ren J., Klein H.G., Sabatino M., Stroncek D.F. Generation of clinical grade human bone marrow stromal cells for use in bone regeneration. Bone 2015, 70:87-92.
55. Torre M.L., Lucarelli E., Guidi S., Ferrari M., Alessandri G., De Girolamo L., Pessina A., Ferrero I. Ex vivo expanded mesenchymal stromal cell minimal quality requirements for clinical application. Stem Cells Dev. 2015, 24:677-685.
56. Capelli C., Pedrini O., Cassina G., Spinelli O., Salmoiraghi S., Golay J., Rambaldi A., Giussani U., Introna M. Frequent occurrence of non-malignant genetic alterations in clinical grade mesenchymal stromal cells expanded for cell therapy protocols. Haematologica 2014, 99:e94-e97.
57. Introna M., Lucchini G., Dander E., Galimberti S., Rovelli A., Balduzzi A., Longoni D., Pavan F., Masciocchi F., Algarotti A., Mico C., Grassi A., Deola S., Cavattoni I., Gaipa G., Belotti D., Perseghin P., Parma M., Pogliani E., Golay J., Pedrini O., Capelli C., Cortelazzo S., D'Amico G., Biondi A., Rambaldi A., Biagi E. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol. Blood Marrow Transplant. 2014, 20:375-381.
58. Perico N., Casiraghi F., Introna M., Gotti E., Todeschini M., Cavinato R.A., Capelli C., Rambaldi A., Cassis P., Rizzo P., Cortinovis M., Marasa M., Golay J., Noris M., Remuzzi G. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin. J. Am. Soc. Nephrol. 2011, 6:412-422.
59. Dignan F.L., Clark A., Amrolia P., Cornish J., Jackson G., Mahendra P., Scarisbrick J.J., Taylor P.C., Hadzic N., Shaw B.E., Potter M.N. Haemato-oncology task force of British Committee for standards in H, British Society for B, Marrow T. Diagnosis and management of acute graft-versus-host disease. Br. J. Haematol. 2012, 158:30-45.
60. Markey K.A., MacDonald K.P., Hill G.R. The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood 2014, 124:354-362.
61. Freedman M.S., Uccelli A. Neurorepair with mesenchymal stem cells: hope or hype. Lancet Neurol. 2012, 11:123-125.
62. Uccelli A., Laroni A., Freedman M.S. Mesenchymal stem cells as treatment for MS - progress to date. Mult. Scler. 2013, 19:515-519.
63. Uccelli A., Laroni A., Freedman M.S. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol. 2011, 10:649-656.
64. Casiraghi F., Perico N., Remuzzi G. Mesenchymal stromal cells to promote solid organ transplantation tolerance. Curr. Opin. Org. Transplant. 2013, 18:51-58.
65. Casiraghi F., Remuzzi G., Perico N. Mesenchymal stromal cells to promote kidney transplantation tolerance. Curr. Opin. Org. Transplant. 2014, 19:47-53.
66. Hervy M., Weber J.L., Pecheul M., Dolley-Sonneville P., Henry D., Zhou Y., Melkoumian Z. Long term expansion of bone marrow-derived hMSCs on novel synthetic microcarriers in xeno-free, defined conditions. PLOS ONE 2014, 9:e92120.
67. Chase L.G., Yang S., Zachar V., Yang Z., Lakshmipathy U., Bradford J., Boucher S.E., Vemuri M.C. Development and characterization of a clinically compliant xeno-free culture medium in good manufacturing practice for human multipotent mesenchymal stem cells. Stem Cells Transl. Med. 2012, 1:750-758.
68. Hartmann I., Hollweck T., Haffner S., Krebs M., Meiser B., Reichart B., Eissner G. Umbilical cord tissue-derived mesenchymal stem cells grow best under GMP-compliant culture conditions and maintain their phenotypic and functional properties. J. Immunol. Methods 2010, 363:80-89.
69. Gastens M.H., Goltry K., Prohaska W., Tschope D., Stratmann B., Lammers D., Kirana S., Gotting C., Kleesiek K. Good manufacturing practice-compliant expansion of marrow-derived stem and progenitor cells for cell therapy. Cell Transplant. 2007, 16:685-696.
70. Chen X., Xu H., Wan C., McCaigue M., Li G. Bioreactor expansion of human adult bone marrow-derived mesenchymal stem cells. Stem Cells 2006, 24:2052-2059.
71. Dos Santos F., Campbell A., Fernandes-Platzgummer A., Andrade P.Z., Gimble J.M., Wen Y., Boucher S., Vemuri M.C., da Silva C.L., Cabral J.M. A xenogeneic-free bioreactor system for the clinical-scale expansion of human mesenchymal stem/stromal cells. Biotechnol. Bioeng. 2014, 111:1116-1127.
72. Rojewski M.T., Fekete N., Baila S., Nguyen K., Furst D., Antwiler D., Dausend J., Kreja L., Ignatius A., Sensebe L., Schrezenmeier H. GMP-compliant isolation and expansion of bone marrow-derived MSCs in the closed, automated device quantum cell expansion system. Cell Transplant. 2013, 22:1981-2000.
73. Cunha B., Aguiar T., Silva M.M., Silva R.J., Sousa M.F., Pineda E., Peixoto C., Carrondo M.J., Serra M., Alves P.M. Exploring continuous and integrated strategies for the up- and downstream processing of human mesenchymal stem cells. J. Biotechnol. 2015, 10.1016/j.jbiotec.2015.02.023.
74. Hupfeld J., Gorr I.H., Schwald C., Beaucamp N., Wiechmann K., Kuentzer K., Huss R., Rieger B., Neubauer M., Wegmeyer H. Modulation of mesenchymal stromal cell characteristics by microcarrier culture in bioreactors. Biotechnol. Bioeng. 2014, 111:2290-2302.
75. Nold P., Brendel C., Neubauer A., Bein G., Hackstein H. Good manufacturing practice-compliant animal-free expansion of human bone marrow derived mesenchymal stroma cells in a closed hollow-fiber-based bioreactor. Biochem. Biophys. Res. Commun. 2013, 430:325-330.